The plasma levels of plasminogen activator inhibitor-1 in subjects with white coat hypertension

Abstract

High plasminogen activator inhibitor-1 (PAI-1) levels are potential risk factors for cardiovascular disease. The risk profile of white coat hypertension (WCHT) has not yet been completely clear. In this study, we aimed to determine the plasma levels of PAI-1, markers of fibrinolysis and increased cardiovascular disease risk, in a group with WCHT and to obtain clinical results by comparing WCHT group with hypertensive and healthy groups. Age and sex matched 30 patients with WCHT, 30 patients with sustained hypertension, and 30 healthy subjects were included in the study. The plasma levels of PAI-1 were significantly higher in sustained hypertension group than in WCHT group (p < 0.01). There were significantly higher levels in patients with WCHT than in control group (p < 0.01). Our data suggests one possible mechanism by which WCHT subjects may be at increased cardiovascular risk.